Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Armstrong, MD
IQVIA Biotech
Study Director - Sue Lee, MD
Aminex Therapeutics, Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Kids Cancer Centre
Sydney, New South Wales, Australia
- Mayo Clinic - Arizona
Phoenix, Arizona, United States
- Mayo Clinic - Florida
Jacksonville, Florida, United States
- Mayo Clinic - Minnesota
Rochester, Minnesota, United States
- Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Fred Hutch Cancer Center - Seattle Cancer Care Alliance
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Nov 2022
- Primary completion
- 12 Dec 2024
- Completion
- 12 Dec 2024
- Last update posted
- 24 Dec 2024
- Registered enrollment
- 15
- Registry id
- NCT05500508
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.